Risk factors for detectable HIV-1 RNA at delivery among women receiving highly active antiretroviral therapy in the women and infants transmission study

Journal of Acquired Immune Deficiency Syndromes

Volumn 54, Issue 1, 2010, Pages 27-34

  Katz, Ingrid T ^a,b,c   Shapiro, Roger ^b,c   Li, Daner ^d   Govindarajulu, Usha ^a,c   Thompson, Bruce ^d   Watts, D Heather ^e   Hughes, Michael D ^f   Tuomala, Ruth ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

^d Clinical Trials & Surveys Corp   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Antiretrovirals; HAART; HIV; MTCT; Pregnancy

Indexed keywords

ABACAVIR; INDINAVIR PLUS RITONAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; RITONAVIR; RITONAVIR PLUS SAQUINAVIR; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; DELIVERY; DRUG ABUSE; FEMALE; HIGH RISK PATIENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MATERNAL AGE; PRIORITY JOURNAL; RISK ASSESSMENT; VIRUS TRANSMISSION;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHEMOPREVENTION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; INFECTIOUS DISEASE TRANSMISSION, VERTICAL; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; RISK FACTORS; RNA, VIRAL; YOUNG ADULT;

EID: 77951689907     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3181caea89     Document Type: Article

References (24)

1. Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection\Michigan 1993-2000. MMWR Morb Mortal Wkly Rep 2002. 51:93-97.
2. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
3. Cooper ER, Charurat M, Mofenson L, et al, Women and Infants' Transmission Study Group. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr. 2002;29:484-494.
4. Centers for Disease Control and Prevention. Enhanced perinatal surveillance\participating areas in the united states and dependent areas, 2000-2003. HIV/AIDS Surveillance Suppl Rep. 2008 13 1-35.
5. Garcia PM, Kalish LA, Pitt J, et al. Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group. N Engl J Med. 1999;341:394-402.
6. Mofenson LM, Lambert JS, Stiehm ER, et al. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. Pediatric AIDS Clinical Trials Group Study 185 Team. N Engl J Med. 1999;341:385-393.
7. Magder LS, Mofenson L, Paul ME, et al. Risk factors for in utero and intrapartum transmission of HIV. J Acquir Immune Defic Syndr. 2005;38: 87-95.
8. European Collaborative Study. Mother-to-child transmission of HIV infection in the era of highly active antiretroviral therapy. Clin Infect Dis. 2005;40:458-465.
9. Thea DM, Steketee RW, Pliner V, et al. The effect of maternal viral load on the risk of perinatal transmission of HIV-1. New York City Perinatal HIV Transmission Collaborative Study Group. AIDS. 1997;11:437-444.
10. Public Health Service Taskforce. Recommendations for use of anti-retroviral drugs in pregnant IV-1 infected women for maternal health and Interventions to Reduce Perinatal HIV transmission in the United States. November 2, 2007. Available at: http://aidsinfo.nih.gov/. Accessed June 5, 2008.
11. European Collaborative Study. Time to undetectable viral load after highly active antiretroviral therapy initiation among HIV-infected pregnant women. Clin Infect Dis. 2007;44:1647-1656.
12. Bartlett JA, Buda JJ, von Scheele B, et al. Minimizing resistance consequences after virologic failure on initial combination therapy: a systematic overview. J Acquir Immune Defic Syndr. 2006;41: 323-331. Review. Erratum in: J Acquir Immune Defic Syndr. 2006;43: 381.
13. Walmsley S, Bernstein B, King M, et al. M98-863 Study Team. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection. N Engl J Med. 2002;346:2039-2046.
14. Anastos K, Schneider M, Gange S, et al. for the Women's Interagency HIV. The association of race, sociodemographic, and behavioral characteristics with response to highly active antiretrovial therapy in women. J Acquir Immune Defic Syndr. 2005:39:537-544.
15. Bardeguez AD, Lindsey JC, Shannon M, et al. for the PACTG 1025 Protocol Team. Adherence to antiretrovirals among US women during and after pregnancy. J Acquir Immune Defic Syndr. 2008;48:408-417.
16. Mellins CA, Chu C, Malee K, et al. Adherence to antiretroviral treatment among pregnant and postpartum HIV-infected women. AIDS Care. 2008; 20:958-968.
17. Sheon AR, Fox HE, Rich KC. The Women and Infants Transmission Study (WITS) of maternal-infant HIV transmission: study design, methods, and baseline data. J Women Health. 1996;5:69-78.
18. National Center for Infectious Diseases Division of HIV/AIDS, Castro KG, Ward JW, Slutsker L, Buehler JW, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992/41(RR-17). Available at: http://www.cdc.gov/ mmwr/preview/mmwrhtml/00018871.htm. Accessed October 8, 2009.
19. Stek AM. Antiretroviral medications during pregnancy for therapy or prophylaxis. Curr HIV/AIDS Rep. 2009;6:68-76.
20. Cressey TR, Lallemant M. Pharmacogenetics of antiretroviral drugs for the treatment of HIV-infected patients: an update. Infect Genet Evol. 2007; 7:333-342.
21. Clark R. Sex differences in antiretroviral therapy-associated intolerance and adverse events. Drug Saf. 2005;28:1075-1083.
22. Mirochnick M, Best BM, Stek AM, et al. PACTG 1026s Study Team. Lopinavir exposure with an increased dose during pregnancy. J Acquir Immune Defic Syndr. 2008;49:485-491.
23. Stek AM, Mirochnick M, Capparelli E, et al. Reduced lopinavir exposure during pregnancy. AIDS. 2006;20:1931-1939.
24. Read JS, Best BM, Stek AM, et al. Pharmacokinetics of new 625 mg nelfinavir formulation during pregnancy and postpartum. HIV Med. 2008; 9:875-882 [Epub 2008 Sep 14].